Clinical Trials
108 trialsDose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
SOAR
University of Toronto
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Institutes of Health Clinical Center (CC)
Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study
Fred Hutchinson Cancer Center
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
SELECT-CAR-NK
Essen Biotech
PREPARE
Institut Bergonié
CAMPERR
Adela, Inc
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
PEPOH
University of Salamanca
LIBERATE
University Health Network, Toronto
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
EARN
Washington University School of Medicine
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
PROACT
Washington University School of Medicine
MECRIS
Region Skane
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
PRIORITY
Institut Bergonié
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
IT-01
Intensity Therapeutics, Inc.
IMPROVED
Zealand University Hospital
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
FUTURE
Assistance Publique Hopitaux De Marseille
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
MOHCCN-O
University Health Network, Toronto
Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET
Academisch Ziekenhuis Maastricht
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
QUANTUM
VitaMed Research LLC
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
AIDS Malignancy Consortium
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
ImmVira Pharma Co. Ltd
RESTORE
Blue Note Therapeutics
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Endobronchial Ultrasound Needle Aspiration With and Without Suction
Università Politecnica delle Marche
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation